Assay validation for identification of hereditary nonpolyposis colon cancer-causing mutations in mismatch repair genes MLH1, MSH2, and MSH6

被引:27
作者
Hegde, M
Blazo, M
Chong, B
Prior, T
Richards, C
机构
[1] Baylor Coll Med, Diagnost Sequencing Lab, Med Genet Labs, Dept Mol & Human Genet, Houston, TX 77030 USA
[2] Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA
关键词
D O I
10.1016/S1525-1578(10)60584-3
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Hereditary nonpolyposis colon cancer (HNPCC, Online Mendelian Inheritance in Man (OMIM) 114500) is an autosomal dominant disorder that is genetically heterogeneous because of underlying mutations in mismatch repair genes, primarily MLH1, MSH2, and MSH6. One challenge to correctly diagnosing HNPCC is that the large size of the causative genes makes identification of mutations both labor intensive and expensive. We evaluated the usefulness of denaturing high performance liquid chromatography (DHFLC) for scanning mismatch repair genes (MLH1, MSH2, and MSH6) for point mutations, small deletions, and insertions. Our assay consisted of 51 sets of primers designed to amplify all exons of these genes. Aft polymerase chain reaction reactions were amplified simultaneously using the same reaction conditions in a 96-well format. The amplified products were analyzed by DHPLC across a range of optimum temperatures for partial fragment denaturation based on the melting profile of each specific fragment. DNA specimens from 23 previously studied HNPCC patients were analyzed by DHPLC, and all mutations were correctly identified and confirmed by sequence analysis. Here, we present our validation studies of the DHPLC platform for HN-PCC mutation analysis and compare its merits with other scanning technologies. This approach provides greater sensitivity and more directed molecular analysis for clinical testing in HNPCC.
引用
收藏
页码:525 / 534
页数:10
相关论文
共 61 条
[1]  
AALTONEN LA, 1994, ANTICANCER RES, V14, P1657
[2]  
Arnold N, 1999, HUM MUTAT, V14, P333, DOI 10.1002/(SICI)1098-1004(199910)14:4<333::AID-HUMU9>3.3.CO
[3]  
2-3
[4]   Use of SSCP analysis to identify germline mutations in HNPCC families fulfilling the Amsterdam criteria [J].
Beck, NE ;
Tomlinson, IPM ;
Homfray, T ;
Frayling, I ;
Hodgson, SV ;
Harocopos, C ;
Bodmer, WF .
HUMAN GENETICS, 1997, 99 (02) :219-224
[5]  
Bellacosa A, 1996, AM J MED GENET, V62, P353, DOI 10.1002/(SICI)1096-8628(19960424)62:4<353::AID-AJMG7>3.0.CO
[6]  
2-S
[7]   Denaturing high-performance liquid chromatography (DHPLC)-based prenatal diagnosis for tuberous sclerosis [J].
Bénit, P ;
Bonnefont, JP ;
Mostefa, AK ;
Francannet, C ;
Munnich, A ;
Ray, PF .
PRENATAL DIAGNOSIS, 2001, 21 (04) :279-283
[8]   Molecular and clinical characteristics of MSH6 variants:: An analysis of 25 index carriers of a germline variant [J].
Berends, MJW ;
Wu, Y ;
Sijmons, RH ;
Mensink, RGJ ;
van der Sluis, T ;
Hordijk-Hos, JM ;
de Vries, EGE ;
Hollema, H ;
Karrenbeld, A ;
Buys, CHCM ;
van der Zee, AGJ ;
Hofstra, RMW ;
Kleibeuker, JH .
AMERICAN JOURNAL OF HUMAN GENETICS, 2002, 70 (01) :26-37
[9]  
BOCKER T, 1999, BIOCHIM BIOPHYS ACTA, V1423, P1
[10]  
Borg A, 2000, INT J CANCER, V85, P796